

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Canceled).
2. (Canceled).
3. (Canceled).
4. (Canceled).
5. (Canceled).
6. (Canceled).
7. (Canceled).
8. (Currently Amended) ~~Compounds according to Claim 1 selected from the group A~~
compound of the formula
N-1-[(4-chlorophenyl)]-N-2-{[4-(2-{dimethylaminomethyl}phenyl)phenyl]-
}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-{[4-(2-{dimethylaminomethyl}phenyl)-
phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-chlorophenyl)]-N-2-{[2-fluoro-4-(2-{dimethylaminomethyl}-
phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-{[2-fluoro-4-(2-{dimethylaminomethyl}-
phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(2-dimethylaminomethylimidazol-1-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-ethynylphenyl)]-N-2-[(4-(2-dimethylaminomethyl-imidazol-1-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(2-dimethylamino-methylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-chlorophenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-ethynylphenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-chlorophenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-ethynylphenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

and/or pharmaceutically usable derivatives, solvates, salts and/or stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Process for the preparation of compounds of the formula I



in which

R denotes Hal, $-C\equiv C-H$, $-C\equiv C-A$ or OA,


R¹ denotes H, =O, Hal, A, OH, OA, A-COO-, Ph-(CH₂)_n-COO-, cycloalkyl-(CH₂)_n-COO-, A-CONH-, A-CONA-, Ph-CONA-, N₃, NH₂, NO₂, CN, COOH, COOA, CONH₂, CONHA, CON(A)₂, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA or =CF₂,

R² denotes H or A,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, OH or Hal,

R³ denotes H, Hal or A,

R⁴ denotes $-C_6H_4-(CH_2)_n-NR^5R^{5'}$, $-C(=NR^5)NR^5R^{5'}$,



R⁵, R^{5'} each, independently of one another, denote H or A,


A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,

according to Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that comprising reacting


a) a compound of the formula II



~~in which R has the meaning indicated in Claim 1,~~

~~is reacted~~ with a chloroformate derivative to give an intermediate carbamate derivative,

~~which is subsequently reacted~~ reacting said intermediate with a compound of the formula III




~~in which~~

~~R¹, R², R³ and R⁴ have the meaning indicated in Claim 1,~~

or

b) reacting a compound of the formula III

~~is reacted~~ with a compound of the formula IV




~~in which~~

~~R has the meaning indicated in Claim 1,~~


or

c) reacting a compound of the formula V



~~in which R³ and R⁴ have the meaning indicated in Claim 1,~~

~~is reacted~~ with a compound of the formula VI



in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group
and

~~R, R¹ and R² have the meanings indicated in Claim 1,~~

and/or converting

a base or acid of the formula I ~~is converted~~ into one of its salts.

10. (Currently Amended) ~~Compounds of the formula I according to Claim 1 as~~

~~inhibitors~~A method of coagulation factor Xa, comprising administering to a host in need thereof a compound of claim 8 or a pharmaceutically useable derivative, salt or stereoisomer thereof.

11. (Canceled).
12. (Currently Amended) ~~Medicaments~~A pharmaceutical composition comprising at least one compound ~~of the formula I~~ according to Claim 1 and/or pharmaceutically usable derivatives, ~~solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and optionally~~pharmaceutically acceptable excipients and/or adjuvants.
13. (Canceled).
14. (Previously Presented) ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament~~A method for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tinnitus, tumours, tumour diseases and/or tumour metastases, comprising administering to a host in need thereof an effective amount of a compound of claim 8 and/or pharmaceutically useable derivatives, salts or stereoisomers thereof.
15. (Previously Presented) Set (kit) consisting of separate packs of
 - (a) an effective amount of a compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,
and
 - (b) an effective amount of a further medicament active ingredient.

16. (Canceled).